Healthcare Industry News: rosuvastatin
News Release - December 22, 2010
Abbott and AstraZeneca End License Agreement for the Development of CERTRIADABBOTT PARK, Ill., Dec. 22, 2010 (Healthcare Sales & Marketing Network) -- Abbott (NYSE:ABT ) announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD™ (rosuvastatin / fenofibric acid delayed release) Capsules. The companies reached this decision after careful consideration of the Complete Response Letter received from the U.S. Food and Drug Administration, the resulting regulatory delay and the commercial attractiveness of the product in the U.S. market.
There will be no financial impact to Abbott's ongoing earnings per share in 2010 or 2011 resulting from this action.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott's FreeStyle(R) Libre 2 iCGM System Now Available to Medicare Beneficiaries
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device